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Populations exposed to Plasmodium falciparum infection develop genetic mechanisms of protection against se-
vere malarial disease. Despite decades of genetic epidemiological research, the sickle cell trait (HbAS) sickle cell
polymorphism, ABO blood group, and other hemoglobinopathies remain the few major determinants in severe
malaria to be replicated across different African populations and study designs. Within a case-control study in a
region of high transmission in Tanzania (n = 983), we investigated the role of 40 new loci identiﬁed in recent ge-
nome-wide studies. In 32 loci passing quality control procedures, we found polymorphisms in USP38, FREM3,
SDC1, DDC, and LOC727982 genes to be putatively associated with differential susceptibility to severe malaria.
Established candidates explained 7.4% of variation in severe malaria risk (HbAS polymorphism, 6.3%; α-thalas-
semia, 0.3%; ABO group, 0.3%; and glucose-6-phosphate dehydrogenase deﬁciency, 0.5%) and the new polymor-
phisms, another 4.3%. The regions encompassing the loci identiﬁed are promising targets for the design of future
treatment and control interventions.
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Malaria is one of the most prevalent infectious diseases
in the world, with ≥225 million cases and 781 000
deaths per year, most involving Plasmodium falciparum
infections in children in sub-Saharan Africa [1]. The
etiology of malaria is complex, with many genetic and
environmental determinants inﬂuencing the natural
variation in response to infection, progression and se-
verity. Disease phenotypes are inﬂuenced by host age,
state of immunity, and genetic background, as well as
parasite genetic make-up [2].
Heritability studies have estimated that approximately
25% of the risk for severe malaria progression is deter-
mined through human genetic factors [2]. The disease
has also exerted signiﬁcant selection pressure on the
human genome, as evidenced by the congruence of ma-
laria parasite prevalence with sickle cell trait (HbAS) and
other hemoglobinopathies, such as thalassemias and glu-
cose-6-phosphate dehydrogenase (G6PD) deﬁciency.
Despite >20 years of candidate gene studies in severe ma-
laria and its clinical subtypes (eg, cerebral malaria), the
HbAS polymorphism remains one of the few determi-
nants to be replicated across different African popula-
tions and study designs [3].
In the past decade, the development of high-throughput
molecular technologies, the sequencing of the human
genome, and progress in understanding human genetic
diversity has allowed candidate gene studies to be aug-
mented by unbiased genome-wide discovery approaches.
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Genome-wide association studies (GWASs) for severe malaria
have not only conﬁrmed the effects of HbAS and such candidates
as HbAC and the ABO blood group, but they have also identiﬁed
other loci putatively associated with disease risk [3–6]. These
novel loci may affect malaria susceptibility directly or indirectly
(through single-nucleotide polymorphism [SNP] correlations
or linkage disequilibrium [LD]) by modulation of the immune
response and/or interfering with the parasite life cycle inside
the host [3–6]. For example, the DDC gene and neighboring loci
(eg, IZKF1) were identiﬁed in a GWAS in a Gambian population
with a predominantly cerebral malaria case mix [3]. Mutations in
DDC are the cause of aromatic L-amino acid decarboxylase deﬁ-
ciency, an inborn error in neurotransmitter metabolism that leads
to combined serotonin and catecholamine deﬁciency.
Polymorphisms in the ATP2B4 locus, encoding a major calci-
um transporting pump, seems to be protective against severe
childhood malaria in Ghana [4] and in a GWAS analysis across
Gambian, Kenyan, and Malawian populations [5].ATP2B4 is up-
stream of LAX1, a transmembrane protein expressed in peripheral
blood lymphocytes and implicated in T and B-cell responsiveness
[5]. Additional work in Ghana has shown protective effects of
ATP2B4 on malaria in pregnancy and related maternal anemia,
suggesting that ATP2B4 variant-associated protection is not lim-
ited to severe childhood malaria [7]. The 3 population GWAS
analysis also revealed a putative region centered on SMARCA5
in chromosome 4 [5], 250 kb upstream of the GYPE/A/B gene
cluster encoding the MNS blood group system, known putative
receptors for the P. falciparum parasite. This genomic region, in-
cluding INPP4B, USP38, GAB1, GUSBP5, FREM3, and GYPB loci
has been implicated as being under ancient selective pressure,
with particularly strong signals for the FREM3 locus, which is
in almost perfect LD with GYPB and GYPA [8].
Other candidates are being identiﬁed through the involvement
of common genetic pathways in susceptibility to, or protection
from, a number of different infectious diseases. For example, the
major histocompatibility complex genes play a central role in the
immune response to pathogens and self antigens, and theHECW
locus has been identiﬁed in Caenorhabditis elegans as affecting
pathogen avoidance behavior [9]. In contrast, other candidates
found in GWAS association or selection analysis have no appar-
ent previous link to infectious disease (eg, OXNAD1, LOC727982,
SDC1, ZSWIM2, and LPHN2) [6].
In the current study, we investigated the role of 114 polymor-
phisms in 40 new candidate loci, including DDC and FREM3,
identiﬁed from previous GWASs [3–6]. As part of a Malaria-
GEN consortial project described elsewhere [6], genotyping as-
says were developed for 114 SNPs at these loci and typed in a
case-control study of severe malaria (n = 983) conducted in
an intense malaria transmission setting in Tanga, Tanzania
[10, 11]. Previous work in the same individuals using 68 SNPs
across well-documented malaria candidate genes (eg, HbAS,
G6PD, major histocompatibility complex class III loci) revealed
only the HbAS polymorphism to be associated strongly with
protection from all forms of severe malaria (P < 10−8) [10].
There were some weaker X chromosome-speciﬁc associa-
tions, with protection from severe malaria phenotypes due to
the G6PD A- alleles (202A/376G) in females. More extensive
genotyping of the G6PD locus revealed that the observed female
heterozygous advantage is due to balancing selection [11]. Sim-
ilarly, 2 SNPs in the gene encoding the CD40 ligand (CD40L,
X chromosome) were associated with severe malarial anemia
(rs3092945) and respiratory distress (rs1126535) in females,
but not through heterozygous advantage, and not in the cohort
overall. The importance of the CD40L locus, as well as ABO (O
group, rs8176719), ATP2B4 (rs10900585), andG6PD (rs1050828),
has been conﬁrmed in a meta-analysis across African populations
(P < 10−4) [12]. In the same multicenter study, the other 22 can-
didates considered previously in the Tanzanian study did not
reach statistical signiﬁcance overall.
Using the new candidate polymorphisms, we ﬁrst set out to
establish whether any were signiﬁcantly associated with severe
malaria phenotypes in Tanzania. We then quantiﬁed the contri-
bution of these loci to protection from severe malaria over and
above that conferred by the established candidate polymor-
phisms, such as HbAS. We found 9 novel SNPs associated
with protection from severe malaria, some affecting different
clinical subtypes, such as cerebral malaria and severe malarial
anemia. These polymorphisms explain an additional 4.3% of
the variation in risk of severe malaria (and 19.2% of the explain-
able variation) over and above the combined 7.4% accounted for
by the HbAS polymorphism (6.3%), α-thalassemia (0.3%), ABO
blood group (0.3%), and G6PD (0.5%) genes. The loci identiﬁed
provide a rich area for further investigation and potential new av-
enues for developing malaria treatment and control measures.
METHODS
Study Participants and Phenotypes
The study was conducted in Teule district hospital and
surrounding villages in Tanga region, Tanzania. Patients with
severe malaria (n = 506), aged 6 months to 10 years, were re-
cruited between June 2006 and May 2007, if they fulﬁlled any
of the following eligibility criteria: history of ≥2 convulsions
in the last 24 hours, prostration (unable to sit unsupported if
<9 months of age or unable to drink at any age), reduced con-
sciousness (Blantyre coma scale score, <5), respiratory distress,
jaundice, severe malarial anemia (hemoglobin, <5 g/dL [mea-
sured with HemoCue system]), acidosis (blood lactate, >5
mmol/L), or hypoglycemia (blood glucose, <2.5 mmol/L). Pa-
tients were deﬁned as having had cerebral malaria if their Blan-
tyre coma scale score was ≤3. Parasite infection was assessed
with rapid diagnostic test (ParaScreen Pan/Pf test for horserad-
ish peroxidase 2) and double-read Geimsa-stained thick blood
ﬁlms. Controls (n = 477) without any recorded history of severe
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malaria were matched for ward of residence, ethnicity, and age,
using household lists during a 4-week period in August 2008.
Study participants resided in 33 geographic wards (Mtindiro,
9.6%; Kwafungo, 8.5%; Mkata, 6.3%; Kwedizinga, 6.0%; others,
each <5.0%) in Tanga region and were predominantly from 7
ethnic groups (Table 1).
Sample Genotyping
DNA was extracted from blood samples as described elsewhere
[10]. The MalariaGEN resource center identiﬁed candidate
SNPs by analyzing multiple GWASs of severe malaria [3, 4, 6]
and used the Sequenom iPlex platform [13] to genotype these
loci, as part of a multicenter consortial study described else-
where [6]. The genotyping assays included 114 SNP positions
across 40 loci (Supplementary Table 1). Genotyping data
from the previously published 68 SNPs, including HbAS
(rs334), HbAC (rs33930165), HbE (rs33950507), and ABO
blood group (rs8176719 and rs8176746) were used for compar-
isons [10, 11]. The α3.7-thalassemia deletion was typed sepa-
rately by polymerase chain reaction [10].
Statistical Analysis
Deviations in genotypic frequencies from Hardy–Weinberg equi-
librium were assessed using χ2 analysis. SNPs were excluded from
analysis if ≥10% of genotype calls were missing, if there was sig-
niﬁcant deviation from Hardy–Weinberg equilibrium in autoso-
mal SNPs (P < .0001) in controls, or if the overall minor allele
frequency was <0.01. Using these criteria, 25 SNPs (8 loci) were
removed, leaving 89 for association analysis (see Supplementary
Table 1). Case-control association analysis using SNP alleles/ge-
notypes was undertaken using logistic regression and including
age, sex, and ethnic group as covariates. We modeled the SNP
of interest assuming several related genotypic mechanisms (addi-
tive, dominant, recessive, heterozygous advantage, and general
models) and reported the minimum P value from these correlated
tests. Epistatic effects between polymorphisms were considered by
inclusion of statistical interactions in these models.
Haplotypes were inferred from genotypes using an expectation-
maximization algorithm [14].Haplotype association testing was
performed using the logistic regression models described above
[14], and LD was estimated using pairwise D′ (and r2) metrics
[15]. To minimize the occurrence of false-positives due to mul-
tiple statistical testing, and using a permutation approach that
accounted for correlation between markers and tests, we esti-
mated associations to be statistically signiﬁcant at P < .008. In
previous work [10], only G6PD A− (376/202) and HbAS poly-
morphisms were statistically signiﬁcant at this threshold. The
proportion of phenotypic variation explained by individual
SNPs was estimated using the modEvA package (version 0.9)
on R-Forge. Tajima’s D metric was used to quantify evidence
of balancing selection [16]. All analyses were performed using
the R statistical package (http://www.r-project.org).
Table 1. Baseline and Clinical Characteristics
Characteristic
No. (%)a
Difference
P Value
Controls
(n = 477)
Cases
(n = 506)
Age, median (range),
mo
2.9 (0.9–10.9) 1.7 (0.2–10.0) <.0001
Female sex 255 (53.5) 236 (46.6) .04
Ethnicity .0005
Mzigua 158 (33.1) 149 (29.4)
Wasambaa 130 (27.3) 130 (25.7)
Wabondei 78 (16.4) 79 (15.6)
Chagga 50 (10.5) 47 (9.3)
Mmbena 23 (4.8) 25 (4.9)
Mngoni 18 (3.8) 19 (3.8)
Pare 15 (3.1) 18 (3.6)
Other 5 (1.0) 39 (7.7)
Blood group .22
O 236 (50.1) 216 (44.4)
A 115 (24.4) 145 (29.8)
B 100 (21.2) 10 (22.0)
AB 20 (4.2) 18 (3.7)
Sickle HbAS (rs334)b <.0001
AA 385 (83.5) 473 (97.9)
AS 76 (16.5) 5 (1.0)
SS 0 (0.0) 5 (1.0)
α-thalassemia .15
αα/αα 224 (47.2) 236 (51.9)
αα/α- 199 (41.9) 184 (40.4)
α-/α- 52 (10.9) 35 (7.7)
G6PD G202A (female) .01
GG 154 (62.6) 159 (71.0)
AG 83 (33.7) 52 (23.2)
AA 9 (3.7) 13 (5.8)
A 51 (20.5) 39 (17.4)
G6PD202A (male) 41 (19.3) 37 (14.7) .23
G6PD A376G (female) .05
AA 83 (33.5) 106 (47.1)
AG 133 (53.6) 85 (37.8)
GG 32 (12.9) 34 (15.1)
G 99 (39.7) 77 (34.0)
G6PD376G (male) 79 (37.1) 90 (36.7) .98
Any severe malaria . . . 506 (100) . . .
Any severe malarial
anemiab
. . . 246 (48.6) . . .
Any cerebral malaria . . . 99 (19.6) . . .
Both severe malarial
anemia and cerebral
malaria
. . . 41 (8.1) . . .
Any respiratory
distress
. . . 146 (28.9) . . .
Acidosisc . . . 291 (57.5) . . .
Abbreviation: HbAS, sickle cell trait.
a Unless otherwise specified, data represent No. (%) of patients or controls.
b Defined as hemoglobin <5 gdL.
c Defined as blood lactate >5 mmol/L.
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RESULTS
The severe malaria case mix (n = 506) included cases of acidosis
(57.5%), severe malarial anemia (48.6%), respiratory distress
(28.9%), and cerebral malaria (19.6%) (Table 1 and Supplemen-
tary Figure 1). Compared with controls (n = 477), case patients
with malaria were younger and more likely to be male, with
fewer from the 7 main ethnic groups (P < .05). As expected,
case patients were less likely to be of blood group O (odds
ratio [OR] for O vs A, 0.726; 95% conﬁdence interval [CI],
.534–.986; P = .04), or to have α-/α- thalassemia (α-/α- vs αα/
αα or αα/α-, 0.639; .401–1.018; P = .06) or sickle cell protective
AS (AS vs other, 0.053; .021–.132; P < 10−17) genotypes. Allele
frequencies for both G6PD202A (case patients vs controls,
16.3% vs 20.0%) and G6PD376G (37.4% vs 38.5%) were slightly
lower in malaria case patients than in controls (P < .02), and
any protective effects were seen predominantly in female and
not male patients (Table 1). In particular, protection was
Figure 1. Association P values for severe malaria. Vertical dashed line represents P value of .008.
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observed in female heterozygotes with G6PD376 (OR for fe-
male AG vs AA/GG, 0.436 [95% CI, .257–.621; P = .00007];
male A vs G, 1.012 [.672–1.522; P = .956]) or G6PD202 (female
AG vs AA/GG, 0.518 [.325–.827; P = .005]; male A vs G, 0.774
[.461–1.300; P = .333]).
Association analysis using the 89 high-quality polymor-
phisms revealed 10 SNPs (6 loci) associated with severe malaria
(Figure 1 and Table 2). These included HbAS (HBB; P < 10−17);
rs4266246 (USP38; P = .0003); rs149914432, rs186790584, and
rs186873296 (FREM3; all P < .0033); rs11899121 (SDC1; P =
.0021); rs10188961 (LOC727982; P = .0028); and rs10249420,
rs7803788, and rs880028 (DDC; P < .0080). No associations
were observed at the ATP2B4 locus (P > .247). The heterozygous
advantage effect of the HbAS-AS genotype was statistically signif-
icant across all clinical phenotypes (OR, 0.021–0.056; P < 10−6)
whereas the rs4266246 (USP38) association was driven by ap-
proximately 50% increased susceptibility to acidosis (OR for ad-
ditive T allele, 1.549; P = .0015) and severe malarial anemia (OR
for additive T allele, 1.443; P = .0048).
For the other severe malaria associations there were only sig-
niﬁcant signals for single clinical phenotypes. The rs11899121
(SDC1) SNP was associated with a approximately 49% reduc-
tion in risk of respiratory distress (OR for CG/GG vs CC geno-
types, 0.505; P = .0025). Similarly, rs10188961 (LOC727982) was
associated with increased susceptibility to acidosis (OR for
additive G allele, 1.488; P = .0011). The most signiﬁcant associ-
ation—between severe malaria and FREM3 (rs149914432)—
arose through a approximately 59% reduced risk of acidosis
(OR for AC vs other genotypes, 0.411; P = .0057). The other pu-
tative FREM3 severe malaria associations did not reach the stat-
istical signiﬁcance threshold for the acidosis phenotype
(rs186790584, P = .009; rs186873296, P = .010). The DDC associ-
ation arose through a heterozygous protective effect against cere-
bral malaria (OR, 0.409; P = .0040). Whereas the rs6457452
SNP (HSPA1B) was associated with 34% reduced risk of severe
malarial anemia (OR for additive T allele, 0.661; P = .0073),
there was weaker evidence for an effect on severe malaria overall
(P = .010).
Table 2. Severe Malaria Associations
Phenotype and SNP
Gene
Name
Allele MAF
Genotype
Comparison OR (95% CI)a P ValueMajor Minor Control Case
Severe malaria
rs334 HBB A S 0.082 0.016 AS vs other 0.056 (.022–.142) 4.0 × 10−18
rs4266246 USP38 C T 0.225 0.313 CT/TT vs CC 1.665 (1.263–2.195) .0003
rs149914432 FREM3 A C 0.060 0.031 AC vs other 0.447 (.265–.752) .0019
rs11899121 SDC1 C G 0.479 0.403 CG/GG vs CC 0.629 (.467–.847) .0021
rs10249420 DDC C G 0.152 0.108 CG vs other 0.605 (.438–.837) .0023
rs186790584 FREM3 A T 0.056 0.030 AT vs other 0.452 (.266–.768) .0026
rs10188961 LOC727982 A G 0.354 0.415 Additive G 1.359 (1.110–1.665) .0028
rs186873296 FREM3 A G 0.055 0.030 AG/GG vs AA 0.471 (.280–.793) .0033
rs7803788 DDC C T 0.152 0.112 CT vs other 0.628 (.456–.866) .0044
rs880028 DDC A G 0.167 0.181 AG vs other 1.497 (1.105–2.026) .0080
Severe malarial anemia
rs334 HBB A S 0.082 0.021 AS vs other 0.047 (.011–.199) 5.2 × 10−11
rs4266246 USP38 C T 0.225 0.332 Additive T 1.549 (1.182–2.031) .0015
rs6457452 HSPA1B C T 0.237 0.177 Additive T 0.661 (.486–.900) .0073
Cerebral malaria
rs334 HBB A T 0.082 0.000 AS vs other 0.000 (NA) 1.5 × 10−7
rs10249420 DDC C G 0.152 0.077 CG vs other 0.409 (.213–.786) .0040
Respiratory distress;
rs334 HBB A S 0.082 0.007 AS vs other 0.086 (.020–.366) 2.5 × 10−6
rs11899121 SDC1 C G 0.479 0.366 CG/GG vs CC 0.505 (.325–.784) .0025
Acidosis
rs334 HBB A T 0.082 0.012 AS vs other 0.021 (.003–.151) 9.8 × 10−14
rs10188961 LOC727982 A G 0.354 0.429 Additive G 1.488 (1.169–1.894) .0011
rs4266246 USP38 C T 0.225 0.314 Additive T 1.443 (1.117–1.862) .0048
rs149914432 FREM3 A C 0.060 0.030 AC vs other 0.411 (.211–.798) .0057
Abbreviations: CI, confidence interval; MAF, minor allele frequency; NA, cannot be estimated; OR, odds ratio; SNP, single-nucleotide polymorphism.
a All ORs were adjusted for age, ethnicity, and sex.
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For the 2 loci with multiple association hits (FREM3 [3 asso-
ciation hits] and DDC [3 association hits]), we assessed the level
of LD within and ﬂanking the gene to inform a haplotype-based
analysis. For the chromosome 4 region containing FREM3 and
USP38 (length, 1.16 megabase pairs), there was high LD within
the genes (minimum D′, 0.998 for FREM3, 0.998 for USP38,
and 0.999 for INPP4B) and some limited evidence that this
linkage extended to SNPs within different genes (maximum D′,
0.893 between FREM3 and USP38) (Figure 2A). Similarly, for the
genomic region on chromosome 7 containing DDC and IZKF1
(length, 255 kilobase pairs), there were several high-LD blocks ,
including 2 covering the association hits (block 1: rs880028,
rs6592961, rs7809758, and rs1817074 [median D′, 0.973];
block 2: rs10249420 and rs7803788 [D′, 1.000]) (Figure 2B).
Figure 2. Linkage disequilibrium, Top left, D′; bottom right, r2. Black represents 0; white, 1. A, Single-nucleotide polymorphisms (SNPs) in FREM3 and
flanking candidate genes on chromosome 4: rs77389579 and rs13103597 (INPP4B), rs4266246 and rs28459062 (USP38), rs7663712 (GAB1), and
rs149914432, rs186790584, and rs186873296 (FREM3). B, SNPs in the DDC and IZKF1 genes on chromosome 7: rs7779749, rs10230385, rs6964823,
rs11552046, rs4132601, rs11980407, and rs6944602 (IZKF1) and rs4947535–rs7800827 (DDC).
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A haplotype analysis using the FREM3 SNPs (rs149914432,
rs186790584, and rs186873296) revealed a 55% reduced risk of se-
vere malaria between the 2 major haplotypes (OR for CTG vs
AAA, 0.448; P = .003) (Table 3). Further analysis accounting for
the genotypic combinations of haplotypes revealed that AAA
/CTG heterozygotes were protected compared with AAA homozy-
gotes (wild-type) (OR, 0.450; P = .0032) (Table 4). There was some
evidence of the combined haplotype effect on acidosis (OR, 0.423;
95% CI, .217–.825; P = .012). These results are consistent with the
heterozygous advantage effects from the single SNP analyses.
Severe malaria haplotype analysis of DDC block 1, which
includes the rs880028 polymorphism, revealed no signiﬁcant as-
sociations (P > .091) (Table 3) although the heterozygous disad-
vantage of this polymorphism was partially recaptured by
considering haplotype combinations (OR for GAGC/AAGC vs
AGAT/ AGAT, 2.794; P = .0088) (Table 4). However, for patients
with cerebral malaria, in whom the frequency of GAGC/AAGC
was low (3 in 99), no haplotypic association was seen (OR, 1.148;
95% CI, .296–4.447; P = .841). The analysis of severe malaria and
DDC block 2 also captured the heterozygous advantage effects of
Figure 2 continued.
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the rs10249420 and rs7803788 polymorphisms when haplotype
combinations were considered (OR for GT/CC vs CC/CC, 0.643;
P = .0068) (Table 4). There was some evidence of this effect only
in patients with cerebral malaria (OR for GT/CC vs CC/CC,
0.476; 95% CI, .256−.883; P = .0185).
The Tajima’s Dmetric was used to determine whether the het-
erozygous association effects in the FREM3 and DDC loci were
due to balancing selection. This seems to be the case forDDC (Ta-
jima’s D, 3.035 for controls vs 2.787 for case patients) but not for
FREM3 (−0.965 vs −1.245), for which increasing positive values
are indicative of balancing selection. The magnitude of the DDC
effect is at the extreme positive tail of an observed negatively cen-
tered Tajima’s D distribution for African populations [17], where
predominantly negative values demonstrate either slow growth
from a small population size or a bottleneck that predates the mi-
gration of the human species out of Africa [17]. Such balancing
mechanisms exist at other malaria candidate loci, including the
HbAS sickle trait [8] and G6PD [11]. There was no evidence of
epistatic effects betweenHbAS, G6PD, α-thalassemia, and the new
candidate loci (USP38, DDC, FREM3, SDC1, and LOC727982) for
severe malaria risk (P > .129).
Finally, we assessed the proportion of variation in the severe
malaria phenotype that is explained by the new candidate loci
(Figure 3). Of the 22.2% of variation explained overall, age, sex,
and ethnicity accounted for 47.2%, and the established gene
candidates accounted for another 33.6% (HbAS, 28.6%; G6PD,
2.2%; α-thalassemia, 1.5%, ABO blood group, 1.2%). The new
candidates accounted for the remaining 19.2% of the explain-
able variation, with USP38 (8.1%), DDC (3.8%), FREM3
(3.0%), SDC1 (2.6%), and LOC727982 (1.7%) all accounting
for more variation than ABO blood group and α-thalassemia
but in aggregate less than the sickle HbAS polymorphism. Over-
all, the newly identiﬁed polymorphisms explain an additional
nominal 4.3% of the variation in risk of severe malaria over
and above the combined 7.4% for HbAS (6.3%), ABO blood
group (0.2%), α-thalassemia (0.3%), and G6PD (0.5%).
DISCUSSION
As noted for historical candidate genes studies, GWAS ﬁndings
are not always replicated across studies or populations, leading to
reporting of false-positive associations and suspicion of the
Table 3. Haplotype Analysis and Severe Malaria Phenotypes
Phenotype and Gene Haplotype
Frequency
P ValueControl Case OR (95% CI)a
Severe malaria
FREM3b AAA 0.941 0.969 1.000 . . .
CTG 0.053 0.024 0.448 (.266–.756) .006
DDC block 1c AGAT 0.642 0.613 1.000 . . .
AAGC 0.175 0.191 1.100 (.855–1.417) .458
AGGC 0.013 0.015 1.580 (.682–3.661) .286
GAAC 0.027 0.019 0.664 (.342–1.291) .228
GAGC 0.136 0.160 1.277 (.962–1.696) .091
DDC block 2d CC 0.847 0.887 1.000 . . .
GT 0.152 0.113 0.724 (.545–.963) .027
Acidosis
FREM3b AAA 0.941 0.971 1.000 . . .
CTG 0.053 0.026 0.479 (.266–.860) .015
Cerebral malaria
DDC block 1c AGAT 0.642 0.606 1.000 . . .
AAGC 0.175 0.200 1.215 (.822–1.795) .421
AGGC 0.013 0.016 1.242 (.341–4.516) .398
GAAC 0.027 0.015 0.634 (.186–2.165) .382
GAGC 0.136 0.163 1.291 (.838–1.988) .298
DDC block 2d CC 0.847 0.914 1.000 . . .
GT 0.152 0.086 0.531 (.300–.940 .030
Abbreviations: CI, confidence interval; OR, odds ratio.
a All ORs were adjusted for age, ethnicity, and sex.
b FREM3: rs149914432, rs186790584, and rs186873296.
c DDC block 1: rs880028, rs6592961, rs7809758, and rs1817074.
d DDC block 2: rs10249420 and rs7803788.
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validity of novel associations [18]. In studies of severe malaria in
African populations, reproducibility is compromised in part by
allelic heterogeneity across ethnic groups [19], differential pat-
terns of LD [18], and the heterogeneity of the phenotype [3]. As-
sociations are further complicated by diversity in Plasmodium
parasite and Anopheles mosquito factors, both genetic and envi-
ronmental, and their interactions with the human host. Applica-
tion of genomic technologies in large, well-designed studies with
detailed characterization of samples and metadata are required to
disentangle these confounding effects. This Tanzanian case-
control study, with complete metadata on a large number of par-
ticipants, standardized phenotypic deﬁnitions and high-quality
genotyping data, provides a solid platform for genomic discovery.
We sought to test, in a setting of high malaria transmission, the
evidence for 40 relatively new loci (114 SNPs) that have been
associated with severe malaria risk in 4 recent GWASs [3–6].
We conﬁrmed the strong protective effects of the HbAS poly-
morphism, as well as the direct or indirect role of SNPs in
5 other loci (USP38, FREM3, SDC1, DDC, and LOC727982).
We could not conﬁrm that polymorphisms in the ATP2B4
locus (rs10900585, rs4951074 [4], rs55868763, rs3753036, and
rs1541255) were associated with severe malaria (P > .25). It is pos-
sible that the ATP2B4 effect established in a West African popu-
lation [4, 7] may be obscured by allelic heterogeneity in the
genomic region which was not captured by the 5 SNPs genotyped.
The DDC locus was associated with severe malaria through a
mechanism underlying the pathogenesis of cerebral malaria and,
although the number of cases was low (n = 99) compared with
other phenotypes, it demonstrates potentially strong genetic ef-
fects mediated through serotonin- and catecholamine-related
pathways. The DDC SNP data, including rs10249420 with its
heterozygous advantage effect, are consistent with those from
analysis of cerebral malaria in a Gambian study [3].Other stud-
ies may have missed this association by having too few cerebral
malaria cases or lacking SNP coverage of the DDC locus [4, 5].
In the Gambian study, a signiﬁcant association was found at
rs1451375 (OR for AC vs other, 0.69; P = .00007), and we ob-
serve some evidence of association in our Tanzanian data (AC
vs other for severe malaria, 0.674 [95% CI, .497–.914,;P = .011];
cerebral malaria, 0.484 [.269–.871; P = .011]).
A full genetic survey of DDC and its surrounding regions fol-
lowed by association testing is required. Our data suggest that
polymorphisms in IZKF1 (60 kb from DDC) are unlikely to ex-
plain the associations with severe malaria, thereby reducing the
amount of sequencing or genotyping required. DDC was found
to be under balancing selection, a potential mechanism of
maintaining protection from severe malaria in a population,
while retaining minimal putative deleterious effects for the
host. Balancing selection has also been observed at the HBB
[8] and G6PD loci [11].
Table 4. Severe Malaria and Combinations of Haplotypes
Gene Haplotypes Controls, % Case Patients, % OR (95% CI)a P Value
FREM3b 1, 1 88.4 94.2 1.000 . . .
1, 2 10.7 5.2 0.450 (.265–.765) .003c
1, 3 0.6 0.2 0.417 (.035–4.977) .490
2, 2 0.2 0.4 0.856 (.074–9.875) .901
DDC
Block 1d 1, 1 41.9 37.9 1.000
1, 2 21.6 22.7 1.074 (.746–1.547) .700
1, 3 2.2 1.3 0.836 (.275–2.545) .753
1, 4 3.5 2.3 0.668 (.286–1.557) .350
1, 5 17.7 21.1 1.348 (.916–1.983) .129
2, 2 4.4 4.0 0.945 (.456–1.958) .878
2, 5 2.6 5.9 2.794 (1.296–6.024) .009c
5, 5 2.8 1.5 0.531 (.191–1.475) .225
Other 3.3 3.4 1.122 (.515–2.445) .772
Block 2e 1, 1 71.2 78.9
1, 2 27.1 19.5 0.643 (0.467–0.885) .007c
2, 2 1.7 1.6 1.097 (.371–3.242) .867
Abbreviations: CI, confidence interval; OR, odds ratio.
a All ORs were adjusted for age, ethnicity, and sex.
b FREM3: rs149914432, rs186790584, and rs186873296 (haplotype 1 represents AAA; 2, CTG; 3, CAA).
c Significant associations (P < .01).
d DDC block 1: rs880028, rs6592961, rs7809758, and rs1817074 (haplotype 1 represents AGAT; 2, AAGC; 3, AGGC; 4, GAAC; 5, GAGC).
e DDC block 2: rs10249420 and rs7803788 (haplotype 1 represents CC; 2, GT).
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The rs4266246 polymorphism (USP38, chromosome 4) was
associated with pleiotropic protection from acidosis, severe ma-
larial anemia, and severe malaria per se. SNPs in USP38 have
been associated with susceptibility to asthma [20], but the gene
lies in a 700-kb region close to malaria candidates in the GYP-
E/A/B gene cluster as well as the SMARCA5 [5] and FREM3
loci. Several SNPs in FREM3 were associated with acidosis and
severe malaria in our study. A study comparing human and
chimpanzee sequences identiﬁed FREM3 as being under ancient
balancing selection [8], but using the case-control data with no
“ancient” ancestral comparison we found no evidence of such a
mechanism operating on a shorter time scale. The rs11899121
(SDC1) and rs10188961 (LOC727982) polymorphisms were asso-
ciated with respiratory distress and acidosis, respectively, as well
as with severe malaria per se. Both loci are located in regions with
sparse reporting of any GWAS signals. Further characterization
of the genetic variation in these regions in Tanzanian individuals
through sequencing could help impute other genotypes for more
detailed SNP association analysis.
Our ﬁnal statistical model included factors with direct or in-
direct genetic underpinning to assess the overall heritability of
susceptibility to severe malaria and apportion this between the
various protective loci. Our estimate that genetic differences ac-
counted for approximately 22% of the variation in the severe
malaria phenotype in the Tanzanian population is very is
similar to an estimate from a more robust family-based study
(25% [2]). Of particular interest, however, is the relative magni-
tude of the individual genetic contributions. The sickle HbAS
polymorphism accounted for a nominal 6.3%, higher than re-
ported elsewhere (2% [2]), and the combination of new loci—
USP38 (1.8%), FREM3 (0.7%), SDC1 (0.6%), DDC (0.8), and
LOC727982 (0.4%)—explain another further 4.3% of the varia-
tion. The contributions of the new loci tend to be greater than the
established effects of ABO blood group (0.2%), α-thalassemia
(0.3%), and G6PD (0.5%), making them enticing targets for fur-
ther investigation, including functional studies.
Additional biological insights and genetic targets are likely to
come from advances in sequencing technologies leading to
whole-genome approaches, replacing GWAS chips that rely
on LD to detect associations. The resulting whole-genome stud-
ies will not only assess genotype-phenotype associations but
will also uncover protective effects by identifying the signatures
of natural genetic selection left by malaria-driven human evolu-
tion. Further insights will come through applying sequencing
technologies to host, parasite, and mosquito DNA and studying
genetic interactions. As here, future studies will require large
numbers of well characterized samples to disentangle the host
genetic contribution to malaria susceptibility and provide ro-
bust biological insights that could lead to the development of
much-needed disease control measures.
Figure 3. Breakdown of explainable variation in the severe malaria association model (nominal percentage, relative percentage). Abbreviations: G6PD,
glucose-6-phosphate dehydrogenase; HbAS, sickle cell trait.
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Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org). Supplementary materials consist of
data provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages regard-
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